Peter Evan Harwin
CIK 1663607 · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$369.67M
Companies
10
Total Filings
24
Lifetime Open-Market Net
-$1.47B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORKA | Director | 1,131,954 | $90.45 | $102.39M | -$1.50B | 2 | 2026-07-01 |
| COGT | Director | — | $40.67 | — | $0 | 6 | 2026-06-11 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| ZBIO | Director | 2,209,025 | $32.29 | $71.33M | $24.03M | 2 | 2025-10-09 |
| JBIO | Director | — | $19.70 | — | $0 | 1 | 2025-05-01 |
| VRDN | Director | — | $19.51 | — | $0 | 5 | 2024-06-28 |
| APGE | Director | — | $134.17 | — | $0 | 1 | 2024-06-07 |
| DNTH | Director | 1,928,503 | $101.61 | $195.96M | $3.38M | 3 | 2023-10-03 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 1 | 2020-10-29 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | — | — | — | $0 | 1 | 2020-08-31 |
Recent Filings · Page 2 of 3
24 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-13 | COGT | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | APGE | Grant (A) | — | $0 | EDGAR |
| 2023-10-03 | DNTH | Buy (P) | +74,010 | $1.01M | EDGAR |
| 2023-09-28 | DNTH | Buy (P) | +90,000 | $1.18M | EDGAR |
| 2023-09-21 | DNTH | Buy (P) | +90,000 | $1.19M | EDGAR |
| 2023-06-16 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | COGT | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | COGT | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | VRDN | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.